Earnings preview of key companies reporting next week and what to look out for.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that just like Europe has stepped up its defence spending ...

The head of Britain’s largest drug company has demanded Europe ramp up spending on medicines amid fears over Donald Trump’s ...

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...

Europe is putting its "ability to protect the health of its own people at risk", the CEO of FTSE 100 giant Astrazeneca has ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...

The approval of a new breast cancer treatment has given hope to thousands of women with an incurable form of the disease.

Platinum Asset Management’s flagship international fund initiated positions in several pharmaceutical companies in the ...

UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

Image source: Getty Images. While elevator-down moves in the Nasdaq Composite ... that can be purchased with $300 while the ...